Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Valion Bio Completes Formulation of Oral Mucosal Entolimod | WAPE

FilingSEC EDGAR8-K

Valion Bio Completes Formulation of Oral Mucosal Entolimod

Oct 1, 2026, 07:45 ET · SEC accepted

StageFormulation Completed

Filing content

Valion Bio announced the successful completion of formulation work for a novel oral mucosal version of Entolimod.

AI summary of the filing. Please also check the source.

Related companies

Valion Bio, Inc.VBIOView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…